시장보고서
상품코드
1485082

방사성 의약품 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측, 유형별, 공급원별, 최종사용자별, 지역별, 경쟁사별(2019-2029년)

Radiopharmaceuticals Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Source, By End user, By Region and Competition, 2019-2029F

발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 180 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

방사성 의약품 세계 시장 규모는 2023년 55억 2,000만 달러에 달했으며, 예측 기간 동안 2029년까지 연평균 5.25%의 꾸준한 성장이 예상됩니다.

방사성 의약품은 핵의학 분야에서 매우 중요한 구성 요소로 등장하여 진단과 치료에 중요한 역할을 하고 있습니다. 이러한 특수 의약품은 방사선을 방출하는 방사성 동위원소를 함유하고 있어 의료 전문가가 다양한 질병을 가시화하고 치료할 수 있도록 돕습니다. 세계 방사성의약품 시장은 기술 발전, 만성질환 유병률 증가, 개인 맞춤형 의료에 대한 수요 증가 등으로 인해 최근 몇 년동안 큰 폭의 성장세를 보이고 있습니다. 세계 방사성의약품 시장은 질병의 조기 진단과 정확한 치료의 중요성이 부각되면서 강력한 성장세를 보이고 있습니다. 시장은 크게 진단용 방사성의약품과 치료용 방사성의약품으로 구분되며, 각각 전체 시장 확대에 기여하고 있습니다. 진단용 방사성의약품은 양전자방사선단층촬영(PET), 단광자방사선전산화단층촬영(SPECT) 등의 영상진단에 널리 사용되며, 장기 및 조직 기능에 대한 귀중한 통찰력을 제공합니다.

시장 개요
예측 기간 2025-2029년
시장 규모 : 2023년 55억 2,000만 달러
시장 규모 : 2029년 74억 3,000만 달러
CAGR : 2024-2029년 5.25%
급성장 부문 진단 방사성 의약품
최대 시장 북미

시장 성장 촉진요인

만성질환 증가가 방사성의약품 세계 시장 견인

정부 이니셔티브와 자금 조달이 방사성 의약품 세계 시장을 주도하고 있습니다.

주요 시장 과제

높은 생산 비용

서플라이 체인 제약조건

주요 시장 동향

기술의 발전

영상 진단 절차 증가

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 방사성 의약품 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 유형별(진단용 방사성 의약품, 치료용 방사성 의약품)
    • 공급원별(원자로 및 사이클로트론)
    • 최종사용자별(병원 및 진료소, 진단 영상 센터, 기타)
    • 기업별(2023년)
    • 지역별
  • 시장 맵

제6장 북미의 방사성 의약품 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 유형별
    • 공급원별
    • 최종사용자별
    • 국가별
  • 북미 : 국가별 분석
    • 미국
    • 멕시코
    • 캐나다

제7장 유럽의 방사성 의약품 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 유형별
    • 공급원별
    • 최종사용자별
    • 국가별
  • 유럽 : 국가별 분석
    • 프랑스
    • 독일
    • 영국
    • 이탈리아
    • 스페인

제8장 아시아태평양의 방사성 의약품 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 유형별
    • 공급원별
    • 최종사용자별
    • 국가별
  • 아시아태평양 : 국가별 분석
    • 중국
    • 인도
    • 한국
    • 일본
    • 호주

제9장 남미의 방사성 의약품 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 유형별
    • 공급원별
    • 최종사용자별
    • 국가별
  • 남미 : 국가별 분석
    • 브라질
    • 아르헨티나
    • 콜롬비아

제10장 중동 및 아프리카의 방사성 의약품 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 유형별
    • 공급원별
    • 최종사용자별
    • 국가별
  • 중동 및 아프리카 : 국가별 분석
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트(UAE)

제11장 시장 역학

  • 성장 촉진요인
  • 과제

제12장 시장 동향과 발전

  • 합병 및 인수(해당하는 경우)
  • 제품 발매(있는 경우)
  • 최근 동향

제13장 Porter의 Five Forces 분석

  • 업계내 경쟁
  • 신규 참여 가능성
  • 공급업체의 힘
  • 고객의 힘
  • 대체품의 위협

제14장 경쟁 구도

  • PharmaLogic Holdings LLC
  • Jubilant Radiopharma
  • China Isotope & Radiation Corporation
  • Siemens Healthineers AG
  • SHINE Technologies, LLC
  • Ion Beam Applications SA
  • Global Medical Solutions
  • BWX Technologies. Inc
  • Coqui Radio Pharmaceuticals Corp.
  • Evergreen Theragnostics, Inc.

제15장 전략적 제안

제16장 리서치사에 대해 & 면책사항

LSH 24.06.04

Global Radiopharmaceuticals Market was valued at USD 5.52 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 5.25% through 2029. Radiopharmaceuticals have emerged as a pivotal component in the field of nuclear medicine, playing a crucial role in diagnostics and therapy. These specialized pharmaceuticals contain radioactive isotopes that emit radiation, enabling healthcare professionals to visualize and treat various medical conditions. The global radiopharmaceuticals market has witnessed significant growth in recent years, driven by technological advancements, increasing prevalence of chronic diseases, and a rising demand for personalized medicine. The global radiopharmaceuticals market has experienced robust growth, with an increasing emphasis on early disease diagnosis and precise treatment. The market is primarily segmented into diagnostic and therapeutic radiopharmaceuticals, each contributing to the overall expansion. Diagnostic radiopharmaceuticals are widely used in imaging procedures like positron emission tomography (PET) and single-photon emission computed tomography (SPECT), providing valuable insights into the functioning of organs and tissues.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 5.52 Billion
Market Size 2029USD 7.43 Billion
CAGR 2024-20295.25%
Fastest Growing SegmentDiagnostic Radiopharmaceuticals
Largest MarketNorth America

Key Market Drivers

Rising Incidence of Chronic Diseases is Driving the Global Radiopharmaceuticals Market

In recent years, the global healthcare landscape has witnessed a significant surge in the incidence of chronic diseases, posing a formidable challenge to healthcare providers and policymakers worldwide. Chronic diseases, such as cancer, cardiovascular diseases, and neurological disorders, are on the rise, necessitating advanced diagnostic and therapeutic solutions. The growing demand for precision medicine has propelled the global radiopharmaceuticals market, playing a pivotal role in the diagnosis and treatment of various chronic conditions. Cancer continues to be a leading cause of morbidity and mortality worldwide. The increasing prevalence of various types of cancer has led to a growing demand for advanced diagnostic tools to detect the disease at an early stage. Radiopharmaceuticals, particularly those used in PET scans, play a crucial role in accurately diagnosing and staging cancer, enabling healthcare professionals to tailor treatment plans for individual patients. Technological advancements in the field of nuclear medicine have led to the development of novel radiopharmaceuticals with enhanced diagnostic and therapeutic capabilities. The integration of artificial intelligence and molecular imaging techniques has further improved the precision and efficiency of radiopharmaceutical applications, driving market growth.

The global population is aging rapidly, leading to an increased prevalence of chronic cardiovascular diseases. Radiopharmaceuticals are instrumental in diagnosing heart conditions, evaluating myocardial perfusion, and assessing cardiac function. As the aging demographic expands, the demand for cardiovascular imaging using radiopharmaceuticals is expected to grow significantly. Neurological disorders, such as Alzheimer's disease and Parkinson's disease, are becoming more prevalent, particularly among the elderly population. PET imaging using radiopharmaceuticals allows for early detection and monitoring of these disorders, facilitating timely intervention and personalized treatment strategies. Radiopharmaceuticals are not limited to diagnostics; they also play a crucial role in therapeutic applications, especially in oncology.

Government Initiatives and Funding is Driving the Global Radiopharmaceuticals Market

Governments across the globe are recognizing the importance of radiopharmaceuticals in improving healthcare outcomes and are actively supporting the industry through various initiatives and funding programs. These initiatives aim to promote research and development, enhance infrastructure, and ensure accessibility to cutting-edge diagnostic and therapeutic solutions. Governments are allocating substantial funds to support research and development activities in the radiopharmaceuticals sector. These funds are crucial in fostering innovation, encouraging the development of new radiopharmaceuticals, and advancing technologies that enhance diagnostic accuracy and treatment effectiveness.

Governments are investing in the establishment and upgrade of nuclear medicine facilities and infrastructure. This includes the procurement of state-of-the-art imaging equipment and the development of specialized radiopharmaceutical production centers. These initiatives are instrumental in ensuring the availability of high-quality radiopharmaceuticals for diagnostic and therapeutic applications. To address the growing demand for skilled professionals in the field of nuclear medicine, governments are initiating training and education programs. These programs aim to enhance the skills of healthcare professionals involved in the handling and administration of radiopharmaceuticals, ensuring the safe and effective use of these agents.

Key Market Challenges

High Production Costs

The production of radiopharmaceuticals involves the synthesis of radioisotopes, which is a complex and resource-intensive process. The limited number of facilities capable of producing these isotopes increases competition and drives up production costs. Ensuring the quality, safety, and stability of the radiopharmaceuticals adds to the intricacy of the manufacturing process. The stringent regulatory requirements for radiopharmaceutical production contribute significantly to the high costs. Adhering to strict quality control measures and ensuring compliance with various international standards demand substantial investments in equipment, personnel, and facilities. Meeting these regulatory standards is crucial to guarantee the safety of patients and healthcare professionals.

Many radioisotopes used in radiopharmaceuticals have short half-lives, ranging from minutes to hours. This necessitates quick and efficient manufacturing processes to ensure the viability of the product upon reaching medical facilities. The need for specialized infrastructure and equipment to handle these short-lived isotopes further adds to the overall production costs. Continuous innovation and research are vital for the development of new radiopharmaceuticals with enhanced diagnostic and therapeutic capabilities. Funding extensive research programs and clinical trials to demonstrate the efficacy and safety of these new compounds is a resource-intensive endeavor, contributing to the overall high production costs. The relatively small market for radiopharmaceuticals limits the opportunities for achieving economies of scale. The production volumes are often lower compared to traditional pharmaceuticals, leading to higher per-unit production costs. This lack of scale efficiencies makes it challenging for manufacturers to reduce costs and offer competitive pricing.

Supply Chain Constraints

Supply chain constraints represent another significant challenge facing the global radiopharmaceuticals market. Radiopharmaceuticals are highly specialized products that require precise manufacturing processes, stringent quality control measures, and specialized infrastructure for production, distribution, and storage. As a result, the radiopharmaceutical supply chain is inherently complex and susceptible to disruptions.

One of the primary supply chain challenges is the limited availability of radioisotopes used in the production of radiopharmaceuticals. Many radiopharmaceuticals rely on isotopes such as technetium-99m (Tc-99m), which have short half-lives and must be produced using nuclear reactors or cyclotrons. However, the global supply of Tc-99m and other critical radioisotopes is often constrained by factors such as reactor shutdowns, supply chain disruptions, and geopolitical tensions.

The transportation and logistics involved in distributing radiopharmaceuticals present additional challenges. Radiopharmaceuticals have strict temperature and radiation shielding requirements to ensure product stability and safety during transit. Delays or mishandling during transportation can compromise product quality and pose radiation safety risks to personnel and the public.

The limited shelf life of radiopharmaceuticals adds complexity to inventory management and distribution logistics. Manufacturers must carefully manage production schedules, distribution networks, and inventory levels to minimize waste and ensure timely delivery to healthcare facilities.

Key Market Trends

Technological Advancements

In the dynamic landscape of healthcare, technological advancements play a pivotal role in shaping the future of medical diagnostics and treatment. One such domain witnessing remarkable growth is the global radiopharmaceuticals market. Radiopharmaceuticals, compounds containing radioactive isotopes, have become indispensable tools in the fields of nuclear medicine and molecular imaging. The surge in technological innovations is propelling this market to new heights, offering enhanced diagnostic capabilities and more targeted therapeutic options. One of the key drivers behind the growth of the radiopharmaceuticals market is the continuous evolution of imaging modalities. The integration of advanced imaging technologies, such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), has significantly improved the accuracy and precision of medical diagnostics. These technologies enable healthcare professionals to visualize and assess physiological processes at the molecular level, allowing for earlier and more accurate disease detection.

PET imaging, for instance, has gained prominence due to its ability to provide detailed information about metabolic processes, aiding in the diagnosis and monitoring of various conditions, including cancer, cardiovascular diseases, and neurological disorders. The development of hybrid imaging systems that combine PET with other imaging modalities, such as computed tomography (CT) or magnetic resonance imaging (MRI), further enhances the diagnostic capabilities of radiopharmaceuticals. Beyond diagnostics, technological advancements are also reshaping the landscape of therapeutic radiopharmaceuticals. Precision medicine, guided by molecular imaging and targeted therapies, is becoming a reality. Advances in radionuclide therapy, particularly in the treatment of cancer, are creating opportunities for more effective and personalized interventions. Targeted alpha-particle therapy, for instance, is gaining attention for its ability to deliver highly localized radiation to cancer cells while sparing surrounding healthy tissue. This approach minimizes collateral damage and reduces the side effects associated with traditional radiotherapy. The development of theranostic agents-radiopharmaceuticals that combine both diagnostic and therapeutic properties-enables clinicians to tailor treatment plans based on individual patient characteristics.

Rise in Diagnostic Imaging Procedures

Primary drivers of growth in the global radiopharmaceuticals market include the increasing demand for diagnostic imaging procedures. Radiopharmaceuticals play a crucial role in nuclear medicine imaging techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), which are used for the diagnosis and staging of various diseases, including cancer, cardiovascular disorders, and neurological conditions.

PET imaging, in particular, has witnessed rapid adoption due to its ability to provide high-resolution, three-dimensional images of metabolic processes within the body. PET radiopharmaceuticals such as fluorodeoxyglucose (FDG) are widely used for oncology imaging, allowing clinicians to detect and monitor tumors, assess treatment response, and plan personalized treatment strategies for cancer patients.

Advancements in hybrid imaging technologies, such as PET/CT and PET/MRI, have further expanded the applications of radiopharmaceuticals in diagnostic imaging. These hybrid imaging modalities combine the functional information provided by PET with the anatomical detail offered by CT or MRI, enabling more accurate localization and characterization of disease processes.

The rise in diagnostic imaging procedures is driven by factors such as the increasing prevalence of chronic diseases, aging population demographics, and growing awareness of the importance of early disease detection and prevention. As a result, the global market for radiopharmaceuticals used in diagnostic imaging is poised for continued growth, with opportunities for innovation and market expansion in emerging applications and regions.

Segmental Insights

Type Insights

Based on the category of type, Diagnostic Radiopharmaceuticals emerged as the dominant segment in the global market for Radiopharmaceuticals in 2023. Diagnostic radiopharmaceuticals are radioisotopes combined with a pharmaceutical agent to create a compound that can be administered to a patient for imaging purposes. These compounds emit gamma rays, which can be detected by imaging devices such as gamma cameras or PET scanners. The ability to visualize the physiological functions of organs and tissues at a molecular level makes diagnostic radiopharmaceuticals an invaluable tool for clinicians. The rising prevalence of chronic diseases, including cancer, cardiovascular disorders, and neurological conditions, has led to an increased demand for accurate diagnostic tools. Diagnostic radiopharmaceuticals provide clinicians with valuable information about the extent and nature of diseases, enabling them to formulate precise treatment plans.

Technological advancements in imaging devices, such as Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET), have significantly contributed to the growth of the diagnostic radiopharmaceuticals market. These technologies offer high-resolution images and improved sensitivity, enhancing the diagnostic capabilities of radiopharmaceuticals.

End User Insights

The Hospitals & Clinics segment is projected to experience rapid growth during the forecast period. Hospitals and clinics are primary healthcare facilities where patients undergo diagnostic imaging procedures. The increasing prevalence of chronic diseases and the growing emphasis on early and accurate diagnosis have led to a surge in the demand for radiopharmaceuticals in these settings. As a result, hospitals and clinics have become major consumers of radiopharmaceuticals, contributing significantly to market growth.

Cancer is a global health concern, and the demand for effective diagnostic and therapeutic solutions is on the rise. Radiopharmaceuticals are extensively used in oncology for cancer imaging, staging, and treatment. The ability of radiopharmaceuticals to target and visualize specific cancer cells makes them invaluable in the diagnosis and monitoring of various types of cancers. Hospitals and clinics are at the forefront of cancer care, offering a comprehensive range of services from screening to treatment. The integration of radiopharmaceuticals into cancer diagnostics and treatment protocols has propelled the demand in these healthcare settings. The increasing incidence of cancer cases worldwide has further boosted the utilization of radiopharmaceuticals in hospitals and clinics, solidifying their dominance in the global market.

Regional Insights

North America emerged as the dominant region in the global Radiopharmaceuticals market in 2023, holding the largest market share in terms of value. North America has been at the forefront of technological innovation in the healthcare sector. The region's commitment to research and development has led to the introduction of cutting-edge radiopharmaceuticals and imaging technologies. This technological leadership enhances diagnostic accuracy and enables more targeted and effective treatments. The robust healthcare infrastructure in North America supports the seamless integration of radiopharmaceuticals into medical practices. Access to state-of-the-art facilities and a well-established network of healthcare providers facilitates the widespread adoption of nuclear medicine procedures, contributing to the region's dominance.

Key Market Players

PharmaLogic Holdings LLC

Jubilant Radiopharma

China Isotope & Radiation Corporation

Siemens Healthineers AG

SHINE Technologies, LLC

Ion Beam Applications SA

Global Medical Solutions

BWX Technologies. Inc

Coqui Radio Pharmaceuticals Corp.

Evergreen Theragnostics, Inc.

Report Scope:

In this report, the Global Radiopharmaceuticals Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Radiopharmaceuticals Market, By Type:

    Diagnostic Radiopharmaceuticals Therapeutic Radiopharmaceuticals

Radiopharmaceuticals Market, By Source:

    Nuclear Reactors Cyclotrons

Radiopharmaceuticals Market, By End User:

    Hospitals & Clinics Diagnostics imaging centre Others

Radiopharmaceuticals Market, By Region:

    North America

United States

Canada

Mexico

    Europe

France

United Kingdom

Italy

Germany

Spain

    Asia-Pacific

China

India

Japan

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Radiopharmaceuticals Market.

Available Customizations:

Global Radiopharmaceuticals market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Radiopharmaceuticals Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Diagnostic Radiopharmaceuticals, Therapeutic Radiopharmaceuticals)
    • 5.2.2. By Source (Nuclear Reactors and Cyclotrons)
    • 5.2.3. By End User (Hospitals & Clinics, Diagnostics imaging centre, Others)
    • 5.2.4. By Company (2023)
    • 5.2.5. By Region
  • 5.3. Market Map

6. North America Radiopharmaceuticals Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Source
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Radiopharmaceuticals Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Source
        • 6.3.1.2.3. By End User
    • 6.3.2. Mexico Radiopharmaceuticals Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Source
        • 6.3.2.2.3. By End User
    • 6.3.3. Canada Radiopharmaceuticals Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Source
        • 6.3.3.2.3. By End User

7. Europe Radiopharmaceuticals Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Source
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Radiopharmaceuticals Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Source
        • 7.3.1.2.3. By End User
    • 7.3.2. Germany Radiopharmaceuticals Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Source
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Radiopharmaceuticals Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Source
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Radiopharmaceuticals Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Source
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Radiopharmaceuticals Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Source
        • 7.3.5.2.3. By End User

8. Asia-Pacific Radiopharmaceuticals Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Source
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Radiopharmaceuticals Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Source
        • 8.3.1.2.3. By End User
    • 8.3.2. India Radiopharmaceuticals Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Source
        • 8.3.2.2.3. By End User
    • 8.3.3. South Korea Radiopharmaceuticals Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Source
        • 8.3.3.2.3. By End User
    • 8.3.4. Japan Radiopharmaceuticals Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Source
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Radiopharmaceuticals Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Source
        • 8.3.5.2.3. By End User

9. South America Radiopharmaceuticals Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Source
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Radiopharmaceuticals Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Source
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Radiopharmaceuticals Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Source
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Radiopharmaceuticals Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Source
        • 9.3.3.2.3. By End User

10. Middle East and Africa Radiopharmaceuticals Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Source
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Radiopharmaceuticals Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Source
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Radiopharmaceuticals Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Source
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Radiopharmaceuticals Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Source
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porters Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. PharmaLogic Holdings LLC
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Jubilant Radiopharma
  • 14.3. China Isotope & Radiation Corporation
  • 14.4. Siemens Healthineers AG
  • 14.5. SHINE Technologies, LLC
  • 14.6. Ion Beam Applications SA
  • 14.7. Global Medical Solutions
  • 14.8. BWX Technologies. Inc
  • 14.9. Coqui Radio Pharmaceuticals Corp.
  • 14.10. Evergreen Theragnostics, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제